PDS Biotech announces FDA clearance of IND apprlication for Versamune MUC1 combo
PDS Biotechnology (PDSB) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application filed in ...
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer InstituteSecondVersamune®platform candidate ...
Precision Medicine Online1d
PDS Biotech Cleared to Begin Trial of Immunotherapy Combo in MUC1-Positive Colorectal Cancer
The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.
PDS Biotech gets IND application clearance for colorectal cancer treatment
PDS Biotechnology (NASDAQ:PDSB) said on Thursday it received U.S. FDA clearance for its Investigational New Drug application ...
Nature25d
Mucins in cancer: function, prognosis and therapy
Expression of the transmembrane mucin MUC1 is upregulated in response to chronic inflammation. Aberrant overexpression of transmembrane mucins is associated with diverse human carcinomas and ...
Hosted on MSN1mon
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m
Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated mucin-1 (TA-MUC1) antibody, from Glycotope for $132.5m. The gatipotuzumab ...